Philips launches RADIQAL study to generate real-world evidence for new ultra-low X-ray dose technolo
May 20, 2025
- Prospective, randomized, unblinded, comparative, international, multi-center clinical investigation
- 824 patients across 6 hospitals in Spain, Czech Republic, Denmark and the US
- Primary objective is to demonstrate that the new technology can reduce overall patient radiation dose without affecting coronary procedure performance.
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the RADIQAL (Radiation Dose and Image Quality Trial) trial. This multicenter, randomized study, sponsored by Philips will enroll 824 coronary artery disease patients across 6 hospitals in Spain, Czech Republic and the US. The first patient in the study was enrolled at Aarhus University Hospital, Denmark.
“The ability to reduce radiation exposure without compromising procedural performance is a key priority in interventional cardiology,” said Dr. Javier Escaned, Professor of Cardiology at Hospital Clínico San Carlos and principal investigator. “It is also important to achieve high-quality angiograms when using diluted contrast media as part of ultra-low contrast procedures. RADIQAL is designed to generate robust, real-world evidence on whether Philips’ new ultra-low X-ray dose technology can reduce radiation exposure for patients and staff without affecting the quality of coronary procedures.”
Coronary artery disease (CAD) is the most frequent type of heart disease affecting millions of people worldwide. It is caused by chronic inflammation of the coronary arteries, which may lead to a gradual obstruction or sudden occlusion of blood flow to the heart muscle. Percutaneous coronary intervention (PCI) is a widely used image-guided, minimally invasive procedure to open blocked coronary arteries and treat CAD. Philips Azurion is an image-guided therapy system which is used for live X-ray imaging during such procedures.
The RADIQAL trial evaluates radiation exposure, image quality and procedural performance between Philips’ new ultra-low dose technology and existing ClarityIQ technology, both integrated into the Azurion image-guided therapy system. The new technology features an ultra-low dose protocol for coronary procedures, reducing X-ray exposure by 50% compared to even the lowest setting currently available on our Azurion systems with ClarityIQ. This technology has obtained CE marking and as such is cleared under the EU MDR regulatory framework*.
“Reducing radiation exposure while maintaining or improving image-quality is one of the most important innovation goals in interventional cardiology,” said Dr. Darshan Doshi, Head of Medical & Clinical at Philips Image-Guided Therapy Devices and Interventional Cardiologist at the Massachusetts General Hospital in Boston, USA. “Interventional cardiologists rely on low-dose, high-quality imaging for confident decision-making throughout multiple procedures each day. Also for patients, especially those with high BMI or with complex conditions requiring repeat interventions, minimizing radiation exposure is increasingly critical.”
* Not cleared as a medical device in FDA-regulated countries. Enrollment in the US has not started.
For further information, please contact:
Joost Maltha
Philips Global External Relations
Tel.: +31 6 10 55 8116
E-Mail: joost.maltha@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachment
- -40℃极寒漠河,海信红焰双高效系列硬核“通关”!
- 莱丽莎为什么是2024年设计师首推墙布品牌
- Gardiner & Theobald Completes Long-Term Strategic Partnership With Hennick & Company
- 半年打卡5场国际展!衡泰信技术突破惊艳全球!
- 老字号 新国货 !热烈祝贺华垦乳业集团荣获“新疆老字号”企业
- 电视剧《足迹》杀青 陈依莎真情演绎岁月变迁之路
- 120架!沃飞长空携手中行构建eVTOL跨境金融生态圈
- 中网智媒用户突破百万:助力中国人工智能迈向新高度
- 献礼七一,“金融诚信林”加入北疆生态防线
- Builder.ai加强领导团队,来自Amazon的Craig Saunders出任新的人工智能副总裁
- 在超市货架前停留不超过 20 秒
- 实力见证!Witsbb健敏思斩获2024樱桃大赏“年度婴童DHA爆款产品大奖”
- 2025年第三期新道学文化沙龙在京举行
- 铺货、跨界、营销三板斧齐发快准狠,旺旺蔡旺庭在江苏掀起饮料大战
- 民建中央副主席孙东生一行莅临钦州市文实中学视察并指导工作
- 三伏天养生秘籍,A.O.史密斯橱下冷热即饮净水机助力健康生活
- View韩国面部轮廓手术前精密检查到底有多重要!
- 道路停车治理难在哪?洞察底层逻辑,循因施策精准破局
- 惠康食品受邀参加蒙古国驻华大使馆重要活动,积极践行“一带一路”理念
- 微信电商平台京健新:打造健康生活方式的新典范
- 5kw升压降压充电器5000w升压电源变换器
- 创意园区系列之:嘉加德必易园
- NTT DATA和Kinaxis合作实现供应链现代化转型
- 鑫永锦黄金:手工匠心与个性定制的完美结合
- 焕新城市商业新地标 济源宝龙广场12月20日盛大启幕
- US Energy Dominance Faces Long-Term Challenges, Wood Mackenzie Report Finds
- 2024年全球电子分销商50强揭晓:Ample Solutions集团入选!
- Akwel: Nine-Month Revenue Down -5.2%
- 徐冬冬《三大队》入围百花奖最佳女配角提名,小透明逆袭成大女主
- “Honda 0”系列纯电动车最新技术成果发布
推荐
-
产业数字化 为何需要一朵实体云? 改革开放前,国内供应链主要依靠指标拉动,其逻 资讯
-
大家一起关注新疆乌什7.1级地震救援见闻 看到热气腾腾的抓饭马上就要出锅、村里大家 资讯
-
一个“江浙沪人家的孩子已经不卷学习了”的新闻引发议论纷纷 星标★ 来源:桌子的生活观(ID:zzdshg) 没 资讯
-
抖音直播“新红人”进攻本地生活领域 不难看出,抖音本地生活正借由直播向本地生活 资讯
-
王自如被强制执行3383万 据中国执行信息公开网消息,近期,王自如新增一 资讯
-
国足13次出战亚洲杯首次小组赛0进球 北京时间1月23日消息,2023亚洲杯小组 资讯
-
奥运冠军刘翔更新社交账号晒出近照 时隔473天更新动态! 2月20日凌晨2点,奥运冠军刘翔更新社交账号晒 资讯
-
周星驰新片《少林女足》在台湾省举办海选,吸引了不少素人和足球爱好者前来参加 周星驰新片《少林女足》在台湾省举办海选,吸 资讯
-
新增供热能力3200万平方米 新疆最大热电联产项目开工 昨天(26日),新疆最大的热电联产项目—&md 资讯
-
透过数据看城乡居民医保“含金量” 缴费标准是否合理? 记者从国家医保局了解到,近期,全国大部分地区 资讯